Christopher Barbieri

Christopher Barbieri, M.D., is a urologic surgeon whose long-term goal is the definition of distinct molecular classes of prostate cancer, functional modeling of these subtypes to define drivers and therapeutic vulnerability, and translation of this information to care of prostate cancer patients. During his Ph.D. training, he studied transcriptional targets of p53 family members, gaining extensive expertise in cancer biology and cell and molecular biology techniques. His post-doctoral work led to the identification and characterization SPOP mutations in prostate cancer, and the definition of SPOP mutant prostate cancer as a distinct molecular subclass. His research focuses on improving molecular classification of prostate cancer and identifying novel drivers, defining the signaling pathways and biology underlying distinct subtypes of the disease, and exposing new therapeutic avenues.